Clinical Trial Update: A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cadonilimab in hepatocellular carcinoma after radical surgery with high risk of recurrence has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Guangxi Medical University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: TERMINATED